16:51 , Apr 13, 2018 |  BC Week In Review  |  Financial News

Mimetas raises $20.5M in series B

Organ-on-a-chip company Mimetas B.V. (Leiden, the Netherlands) raised $20.5 million on April 11 in a series B round led by new investor European Life Sciences Growth Fund. New investors Aglaia Oncology Fund II, Korys, Cathay...
00:53 , Jun 3, 2017 |  BioCentury  |  Finance

Clever chemistry

Three of Inthera Bioscience AG 's seed investors returned for a CHF10.5 million ($10.8 million) series A round to bring the company's lead protein-protein interaction inhibitor to the clinic. Merck Ventures led the round, which...
22:27 , Mar 16, 2017 |  BC Innovations  |  Product R&D

Neo wave

The central thesis in the increasingly hot field of neoantigens is to pick mutations from patient tumors and turn them into personalized immunotherapies. While companies are staking out their space by defining how they will...
08:00 , Dec 21, 2015 |  BC Week In Review  |  Financial News

Inthera Bioscience completes venture financing

Inthera Bioscience AG , Zurich, Switzerland   Business: Cancer   Date completed: 2015-12-15   Type: Venture financing   Raised: EUR3.4 million ($3.7 million)   Investors: MS Ventures; Aglaia Oncology Fund; Novo Seeds; EVA Basel  ...
07:00 , Sep 7, 2015 |  BC Week In Review  |  Financial News

Merus completes venture financing

Merus B.V. , Utrecht, the Netherlands   Business: Antibodies, Cancer   Date completed: 2015-08-26   Type: Venture financing   Raised: Not disclosed   Investors: Sofinnova Ventures; Novo A/S ; RA Capital Healthcare Fund L.P.; Rock...
07:00 , Sep 7, 2015 |  BioCentury  |  Finance

Crossing, not yet listing

While a financing laden with U.S. crossover investors typically signals a European biotech's near-term plans to list on NASDAQ, that's not necessarily so for Merus B.V .'s series C round. The reason, said RA Capital's...
00:36 , Aug 27, 2015 |  BC Extra  |  Financial News

Merus raising EUR 72.8M series C

Merus B.V. (Utrecht, the Netherlands), which develops bispecific antibodies for cancer, raised an undisclosed amount of money in the first tranche of a EUR 72.8 million ($83.6 million) series C round led by new investors...
07:00 , May 25, 2015 |  BioCentury  |  Finance

Cash cravings

BioCentury's 13th annual European Iceberg survey foresees record financing demand, driven on the public side by higher burn rates and the number of companies joining the group via IPOs, and on the private side by...
07:00 , May 26, 2014 |  BioCentury  |  Finance

Europe's Iceberg 2014: Premier League teams

Competing in biotech's Premier League requires deep pockets, long term planning and the risk appetite to pursue novel technologies or targets that don't always pan out. BioCentury's 12th annual European Iceberg survey reveals that for...
07:00 , Oct 14, 2013 |  BioCentury  |  Finance

Betting on Biclonics

Betting on Biclonics Merus B.V. attracted a trio of pharma investors to its €31 million ($41.9 million) extension of a series B round, which it hopes will be enough to move its lead bispecific cancer...